WHO Launches New Training Manual to Improve Early Breast Cancer Detection and Treatment

The World Health Organization (WHO) has launched a training manual to help countries find breast cancer sooner and treat it more completely.

It arrives with a survival gap behind it: women diagnosed in poorer countries are far less likely to survive five years after diagnosis than women in wealthier ones.

WHO said in a news release on 19 October 2026 that the Global Breast Cancer Initiative (GBCI) Training Manual is written for programme managers, the people who plan and run cancer services.

It turns WHO's global recommendations into step-by-step guidance that countries can adapt at national, subnational and facility levels.

Its modules cover prevention, early detection, diagnosis and treatment, along with health products and technologies (medical supplies and equipment), multidisciplinary team-based care (different specialists working together) and patient navigation.

Finding it early

The manual asks countries to aim for more than 60% of invasive breast cancers to be diagnosed at an early stage, specifically stages I or II.

Doctors classify cancer into stages according to how far it has developed or spread.

Stages I and II are generally considered early-stage breast cancer.

WHO says treatment aimed at a cure is most effective, best tolerated and least costly when breast cancer is diagnosed at this point.

Why WHO is pressing the point

The reason sits in survival estimates WHO published on 8 July 2026, its first estimates covering all 194 Member States.

The estimates measure five-year net survival among women diagnosed between 2017 and 2021.

Net survival accounts for the possibility of death from causes other than breast cancer.

Across all countries, the global median five-year net survival was 77.8%.

That middle figure hides a wide split.

In low-income countries, the median five-year net survival was 41.9%, compared with 60.1% in lower-middle-income countries and 87.3% in high-income countries.

WHO also reported five-year net survival of 39.1% in its African Region, 84.0% in the European Region and 88.5% in the Region of the Americas.

WHO estimated that breast cancer caused about 694,000 deaths worldwide in 2024, with around 70% occurring in low- and middle-income countries.

What WHO says lies behind the gap

In its June 2022 flyer introducing the Global Breast Cancer Initiative, WHO identified three major challenges behind unequal breast cancer outcomes: cancers being detected at advanced stages, limited diagnostic and treatment services, and breast cancer care not being adequately included in universal health coverage.

Universal health coverage aims to ensure that people can access essential health services without suffering financial hardship.

The 2026 survival estimates point to the importance of early diagnosis.

WHO found that the stage at which breast cancer was diagnosed was a key predictor of survival, with lower survival in countries where cancers were more likely to be detected at later stages.

After the diagnosis

The manual's reach goes beyond detection, and so do WHO's targets.

The Global Breast Cancer Initiative uses three main strategies: health promotion for early detection, timely breast diagnosis, and comprehensive breast cancer management.

Alongside the early-diagnosis target sit two others.

The first is for diagnostic evaluation, imaging, tissue sampling and pathology to be completed within 60 days.

The second is for more than 80% of patients to undergo multimodality treatment without abandonment.

Multimodality treatment combines different approaches, such as surgery, chemotherapy and radiotherapy, as appropriate.

A woman whose cancer is detected early but who waits months for a diagnosis, or who starts treatment and cannot complete it, may still face delays that undermine her chances of survival.

The three pillars are designed to address different stages of that pathway.

The first promotes awareness of breast cancer signs and symptoms, risk reduction and the reduction of stigma around breast health.

WHO's goal is for more than 60% of invasive breast cancers to be diagnosed at stage I or II.

The second focuses on timely diagnosis, including public and health worker education and referral to diagnostic services.

Its target is to complete diagnostic evaluation, imaging, tissue sampling and pathology within 60 days.

The third focuses on comprehensive breast cancer management, including access to surgery, chemotherapy and/or radiotherapy, rehabilitation and palliative care.

Its target is for more than 80% of patients to undergo multimodality treatment without abandoning it.

Two of the new manual's modules address parts of this challenge.

One focuses on care delivered by a team of different specialists.

The other covers patient navigation, which WHO describes as an approach designed to guide patients through complex cancer care systems and address barriers to health care and social services.

Where the counting stops

The survival figures carry an important limitation.

The study, involving researchers at the International Agency for Research on Cancer (IARC), WHO and partner institutions, combined available cancer-survival data with other information to estimate five-year net survival across all 194 WHO Member States.

Observed survival data came from cancer registries in 67 countries. For countries without observed survival estimates, researchers relied on statistical modelling.

The estimates therefore do not all come from directly observed survival records, and the availability and quality of underlying data vary between countries.

Among 36 countries WHO classified as fragile or affected by conflict, only two had observed data.

The study, published in Nature Medicine, was funded by the Republic of Korea, St. Jude Children's Research Hospital in the United States and City Cancer Challenge.

A baseline, and a test

WHO said several countries have already shown interest in the manual.

The initiative is working with partners in Ethiopia, Eswatini and the Philippines to adapt it and integrate it into national training programmes.

Launched in 2021, the Global Breast Cancer Initiative aims to reduce breast cancer mortality by 2.5% per year.

WHO says achieving this target over 20 years could save 2.5 million lives.

WHO described the July survival estimates as a baseline against which countries can track progress.

Whether the manual helps narrow the survival gap, particularly in countries with fewer diagnostic and treatment resources, is something future data will help establish.